Project Grant R21MH140169
Award Date 8/11/26
Completion Date 8/10/28
Dollars Obligated $466K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- The National Institute of Mental Health awarded Massachusetts General Hospital $453,750 under the Mental Health Research Grants program (CFDA 93.242) on September 1, 2026, to develop a closed-loop system for assessing target network engagement using concurrent transcranial magnetic stimulation and functional MRI. The recipient is developing a flexible radiofrequency coil array (the RF Cap) that enables functional MRI acquisition simultaneously with transcranial magnetic stimulation in a...
- The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $790,560 under the Mental Health Research Grants program (CFDA 93.242) on April 1, 2026. The award funds development of advanced artificial intelligence models to predict differential antidepressant treatment responses by integrating electronic health records and genomic data. Aim 1 involves building a large language model-based, human-in-the-loop active learning framework to...
- The National Institute of Mental Health awarded the President and Fellows of Harvard College, through its Harvard T.H. Chan School of Public Health division, $418,000 on August 10, 2026, to identify epigenetic biomarkers that predict the risk and progression of depression among young adolescents under the Mental Health Research Grants program (CFDA 93.242). The recipient will investigate how DNA methylation and microRNA expression mediate the effects of early life stress on adolescent...
- The National Institute of Mental Health awarded the University of Miami $731,258 on March 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to map neural dynamics linked to major depressive disorder and generalized anxiety disorder using high-stakes real-world events. The recipient will conduct fMRI neuroimaging across five sessions with 144 undergraduate participants—72 diagnosed with GAD or MDD and 72 controls—leveraging naturally occurring emotional events during...
- The National Institute of Mental Health awarded Brigham & Women's Hospital Inc. $863,825 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a double-blind, confirmatory efficacy trial comparing imaging-based targeting versus scalp-targeted accelerated transcranial magnetic stimulation (ATMS) for treatment-resistant major depressive disorder. The trial will enroll 120 participants to test whether imaging-targeted ATMS, using Stanford Accelerated...
- The National Institute of Mental Health awarded The McLean Hospital Corporation $179,096 on June 18, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate neurocognitive mechanisms underlying negative retrieval bias in major depressive disorder. The recipient will conduct research to distinguish between two competing mechanisms that may explain how depression disrupts emotional memory: increased familiarity (depression strengthens evidence for all negative...
- The National Institute of Mental Health (NIMH) awarded Massachusetts General Hospital a $1.46M Project Grant under the Mental Health Research Grants program (CFDA 93.242) on September 15, 2025, to develop and implement a novel therapeutic intervention combining real-time functional magnetic resonance imaging (fMRI) neurofeedback with mindfulness-based training to address repetitive negative thinking (RNT) in adolescents at risk for serious mental illness. The 24-month project will deliver a...
- The National Institute of Mental Health awarded Northwestern University $714,760 on July 21, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a neuroimaging ancillary study investigating dopaminergic mechanisms of depression and antidepressant response in persons with HIV. The study will enroll 48 participants from a larger clinical trial comparing pramipexole (a dopamine agonist) against escitalopram (an SSRI) for antidepressant efficacy in major depressive...
- The National Institute of Mental Health awarded The Research Foundation for The State University of New York $437,125 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a preliminary positron emission tomography study quantifying the mechanism of transcranial magnetic stimulation in depression. The recipient, operating as Stony Brook University, will investigate the relationship between repetitive transcranial magnetic stimulation (rTMS)—an FDA-approved...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $839,815 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a clinical and translational research project investigating neuroimmune mechanisms of depression and anhedonia. The project tests the hypothesis that heightened peripheral immune function and increased blood-brain barrier permeability contribute to major depressive disorder and anhedonia severity. Work is...